Imperial College London

DrRichardNicholas

Faculty of MedicineDepartment of Brain Sciences

Professor of Practice (Neurology)
 
 
 
//

Contact

 

r.nicholas

 
 
//

Location

 

12L12CLab BlockCharing Cross Campus

//

Summary

 

Publications

Citation

BibTex format

@inproceedings{Gallagher:2018,
author = {Gallagher, P and McGuigan, C and Nicholas, R and Hobart, J and Ford, H and Petheram, K and Sharrack, B and Robertson, N and Mazibrada, G and Scolding, N and Wilson, M and Pearson, O and Jones, J and Overell, J},
pages = {99--100},
publisher = {SAGE PUBLICATIONS LTD},
title = {Alemtuzumab after natalizumab SWitch in evolving rapidly severe multiple sclerosis (ANSWERS MS): long-term UK & Ireland experience.},
url = {http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000446861400151&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202},
year = {2018}
}

RIS format (EndNote, RefMan)

TY  - CPAPER
AU - Gallagher,P
AU - McGuigan,C
AU - Nicholas,R
AU - Hobart,J
AU - Ford,H
AU - Petheram,K
AU - Sharrack,B
AU - Robertson,N
AU - Mazibrada,G
AU - Scolding,N
AU - Wilson,M
AU - Pearson,O
AU - Jones,J
AU - Overell,J
EP - 100
PB - SAGE PUBLICATIONS LTD
PY - 2018///
SN - 1352-4585
SP - 99
TI - Alemtuzumab after natalizumab SWitch in evolving rapidly severe multiple sclerosis (ANSWERS MS): long-term UK & Ireland experience.
UR - http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000446861400151&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202
ER -